[Excretion of beta-2-microglobulin and Tamm-Horsfall protein in patients undergoing a conditioning regimen before bone marrow transplantation].
This study aimed assess function of renal tubules in patients undergoing conditioning regimen before bone marrow transplantation. The examined group comprised 19 patients. 13 of them underwent autologuous bone marrow transplantation (ABMT), or autologuous peripheral blood stem cells transplantation (APBSCT). These patients were treated with Cyclophosphamide (Cy) (120 mg/kg), Etoposide (1.6-1.8 g/m2) and Carmustine (400-450 mg/m2). The remaining 6 patients underwent allogenic bone marrow transplantation (BMT). They were treated with Cy 200 mg/kg or with Cy 120 mg/kg and Busulfan 16 mg/kg (doses given are the total amount or respective drugs were administered during the whole conditioning regimen). Urinary excretion of beta-2MB and THP was assessed a) before the conditioning regimen was started, b) one day before completion of it, and c) one day before bone marrow transplantation. In ABMT/APBSCT patients urinary excretion of beta-2-MG was significantly higher before and during conditioning regimen as compared with baseline value (3309 +/- 1123.7 vs 3919 +/- 1417.8 vs 246.7 +/- 50.3 mg/24h, respectively, p < 0.05). Urinary excretion of THP in these patients was significantly higher only during the conditioning regimen (90.6 +/- 14.3 vs. 30.4 +/- 6.24 mg/24h, p < 0.0002). In BMT patients conditioning regimen was followed by similar but less marked changes of urinary excretion of beta-2-MG and THP as compared with ABMT/APBSCT patients.


CONCLUSIONS
1. Conditioning regimen do influence significantly function of proximal and distal renal tubules. 2. The extent of disturbed function of renal tubules seems to depend on kind of medication that is given during the conditioning regimen.
Franek
E
E
Klinika Nefrologii Slaskiej Akademii Medycznej, Katowice.
Kokot
F
F
Wojnar
J
J
Wacławik
A
A
Duława
J
J
Wiecek
A
A
Markiewicz
M
M
Hołowiecki
J
J
D000276:Adjuvants, Immunologic / Q000652:urine*; D000328:Adult; D016026:Bone Marrow Transplantation / Q000502:physiology*; D002066:Busulfan / Q000009:adverse effects; D002330:Carmustine / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000009:adverse effects; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007684:Kidney Tubules / Q000187:drug effects*; D008297:Male; D009088:Mucoproteins / Q000652:urine*; D011300:Preoperative Care; D058949:Uromodulin; D001613:beta 2-Microglobulin / Q000652:urine*
D000276:Adjuvants, Immunologic; D007166:Immunosuppressive Agents; D009088:Mucoproteins; C548612:UMOD protein, human; D058949:Uromodulin; D001613:beta 2-Microglobulin; D005047:Etoposide; D003520:Cyclophosphamide; D002066:Busulfan; D002330:Carmustine
Wydalanie beta-2-mikroglobuliny i białka Tamma-Horsfalla z moczem u chorych poddanych kondycjonowaniu przed przeszczepieniem szpiku.